Advertisement
U.S. markets open in 6 hours 15 minutes

23andMe Holding Co. (ME)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.4709+0.0271 (+6.11%)
At close: 04:00PM EDT
0.4823 +0.01 (+2.42%)
After hours: 07:49PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.4438
Open0.4500
Bid0.5363 x 1100
Ask0.5425 x 1000
Day's Range0.4260 - 0.4889
52 Week Range0.4260 - 2.3200
Volume9,401,805
Avg. Volume7,087,856
Market Cap227.406M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-1.1100
Earnings DateMay 26, 2024 - May 30, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.43
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ME

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • 23andMe Holding Co.
    Analyst Report: 23andMe Holding Co.23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
    Rating
    Fair Value
    Economic Moat
    2 years agoMorningstar
View more
  • GlobeNewswire

    23andMe Launches New Genetic Reports on Common Forms of Cancer

    23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (PRS) developed by 23andMeSOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer. The reports are based on statistical models know

  • GlobeNewswire

    23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

    23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new non-clinical insights for 23ME-00610, targeting the CD200R1 pathwaySOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced an oral presentation and two poster presentations on two of

  • Insider Monkey

    20 Most Valuable Digital Health Companies In The US

    In this article, we will be taking a look at the 20 most valuable digital health companies in the US. If you are not interested in reading about the global health market, head straight to the 5 Most Valuable Digital Health Companies In The US. As of the latest data, several digital health companies stand […]